Clene (NASDAQ: CLNN) to Present at 2024 Maxim Healthcare Virtual Summit and ThinkEquity Conference 2024
Clene (NASDAQ: CLNN) and its subsidiary to present at two investor conferences in October, showcasing their focus on treating neurodegenerative diseases and improving mitochondrial health.
This news matters as it highlights Clene's efforts to address neurodegenerative diseases, providing potential insights into the future of treatment for conditions like ALS and MS. Investors and those affected by these diseases should take note of Clene's developments in this space.